De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sintx Technologies Toekomstige groei

Future criteriumcontroles 1/6

De winst van Sintx Technologies zal naar verwachting dalen met 30% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 7.6% per jaar. De winst per aandeel zal naar verwachting afnemen met 156.1% per jaar.

Belangrijke informatie

-30.0%

Groei van de winst

-156.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	15.8%
Inkomstengroei	7.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	20 Jun 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:1110 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	3	-14	N/A	-11	2
12/31/2024	3	-12	N/A	-11	2
6/30/2024	3	-9	-12	-11	N/A
3/31/2024	3	-9	-12	-12	N/A
12/31/2023	3	-8	-15	-14	N/A
9/30/2023	2	-14	-14	-13	N/A
6/30/2023	2	-14	-14	-13	N/A
3/31/2023	2	-14	-13	-12	N/A
12/31/2022	2	-16	-12	-10	N/A
9/30/2022	1	-10	-12	-11	N/A
6/30/2022	1	-10	-14	-11	N/A
3/31/2022	1	-10	-14	-10	N/A
12/31/2021	1	-9	-14	-10	N/A
9/30/2021	1	-9	-13	-10	N/A
6/30/2021	0	-9	-10	-10	N/A
3/31/2021	0	-11	-9	-9	N/A
12/31/2020	1	-17	-9	-9	N/A
9/30/2020	1	-16	-9	-9	N/A
6/30/2020	1	-15	-8	-8	N/A
3/31/2020	1	-14	-8	-8	N/A
12/31/2019	1	-7	-7	-6	N/A
9/30/2019	1	-8	-6	-6	N/A
6/30/2019	0	-15	-7	-7	N/A
3/31/2019	0	-22	-9	-9	N/A
12/31/2018	0	-24	-9	-9	N/A
9/30/2018	N/A	-24	-8	-8	N/A
6/30/2018	-6	-17	-7	-7	N/A
3/31/2018	-3	-9	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	4	-5	N/A	-6	N/A
6/30/2017	13	-15	N/A	-8	N/A
3/31/2017	14	-18	N/A	-8	N/A
12/31/2016	15	-21	N/A	-7	N/A
9/30/2016	17	-22	N/A	-7	N/A
6/30/2016	18	-21	N/A	-6	N/A
3/31/2016	19	-22	N/A	-8	N/A
12/31/2015	19	-24	N/A	-9	N/A
9/30/2015	20	-31	N/A	-10	N/A
6/30/2015	21	-26	N/A	-11	N/A
3/31/2015	22	-33	N/A	-15	N/A
12/31/2014	23	-33	N/A	-15	N/A
9/30/2014	23	-22	N/A	-16	N/A
6/30/2014	23	-20	N/A	-15	N/A
3/31/2014	23	-9	N/A	-11	N/A
12/31/2013	22	-8	N/A	-10	N/A
9/30/2013	23	-33	N/A	-9	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 1110 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 1110 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 1110 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 1110 ( 7.6% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van 1110 ( 7.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 1110 naar verwachting over 3 jaar hoog zal zijn

Sintx Technologies Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

No longer forecast to breakeven

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.11 loss in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Full year 2020 earnings released: US$1.01 loss per share (vs US$4.82 loss in FY 2019)

Sintx Technologies, Inc. Announces the Fabric Technology Shown to Inactivate Upon contact SARS-CoV-2, the Virus Causing the Covid-19 Pandemic

SINTX Technologies, Inc. Submits Master Access File to FDA for Silicon Nitride-Polymer Composite Material

O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19

Sintx Technologies Enters into Patent License Agreement with O2 Design, Inc. to Commercialize Face Masks and Mask Filter

New 90-day high: €1.79

New 90-day low: €1.30

Revenue misses expectations

Third quarter 2020 earnings released: US$0.11 loss per share

SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Common Flu, COVID-19, and Other Viral Diseases

SINTX Technologies, Inc. Develops New Mask Fabric with Silicon Nitride

SINTX Technologies Appoints Michael Marcroft as Vice President of Business Development

Sintx Technologies, Inc. Hires Don Bray as Vice President of Business Development

First half earnings released

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $8.196 million.

New 90-day high - €2.26

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

Sintx Technologies Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $4.128 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten